Charming Medical vs NewGenIvf
MCTA and NIVF side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MCTA and NIVF compare
NewGenIvf grew revenue faster over the last twelve months (336% versus −22.7% for Charming Medical).
NewGenIvf keeps more of each dollar of sales as profit, with a net margin of 41.7% compared with −0.47% at Charming Medical.
NewGenIvf scores higher on the StockData Score (7 against 3 for Charming Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MCTA | NIVF |
|---|---|---|
| Size and price | ||
| Share price | $29.35 | $0.231 |
| Change, 1 year | 33.3% | −100.0% |
| Beta (5Y) | 0.85 | 2.87 |
| Employees | 29 | 87 |
| StockData Score | ||
| Total score | 3 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −22.7% | 336% (better) |
| Net income growth (TTM) | −102% | – |
| EPS growth (TTM) | −100% | – |
| Profitability | ||
| Gross margin | 99.3% (better) | 4.0% |
| Operating margin | −0.61% (better) | −45.2% |
| Net margin | −0.47% | 41.7% (better) |
| FCF margin | −32.4% (better) | −46.7% |
| Return on equity | −0.87% | 77.9% (better) |
| Return on invested capital | −13.7% (better) | −70.9% |
| Financial health | ||
| Debt / equity | 0.04 | – |
| Interest coverage | −1.9× (better) | −17.4× |
| Current ratio | 1.89 (better) | 1.06 |
| Piotroski F-score | 2 | 5 (better) |
| Ownership | ||
| Held by institutions | 0.24% | – |
| Held by insiders | 71.9% | – |
| Insider net buying, 12 months | – | $4.2M |
| Short interest, % of float | 11.5% | – |
Go deeper
- MCTA stock overview
- MCTA income statement
- MCTA valuation and score
- NIVF stock overview
- NIVF income statement
- NIVF valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.